Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

T2 Biosystems Receives CE Mark for T2Bacteria™ Panel Enabling Commercialization in Europe

July 18, 2017
LEXINGTON, Mass., July 18, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, announced today that it has received a CE…
READ MORE

Menlo Therapeutics Raises $50M

July 18, 2017
MENLO PARK, Calif., July 18, 2017 /PRNewswire/ -- Menlo Therapeutics Inc. announced today that the company has raised $50M to advance development of serlopitant, a novel NK-1 receptor antagonist, as a once-daily oral treatment…
READ MORE

Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections

July 17, 2017
BOSTON, July 17, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today positive top-line results from a pivotal Phase 3 clinical study comparing its once-daily, oral investigational antibiotic, omadacycline, to twice-daily oral linezolid…
READ MORE